Q-omics provides the consensus-scored SH2D4B profile across patient tissues and cancer cell-line models. SH2D4B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SH2D4B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SH2D4B RNA expression shows 15,862 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, HNSC, and TGCT as cancer lineages where SH2D4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH2D4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH2D4B survival associations across molecular data types. SH2D4B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH2D4B RNA expression–survival associations across cancer types. High SH2D4B expression shows unfavorable associations in ACC, KICH and LUSC, but favorable associations in CESC, UVM and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SH2D4B RNA expression.
This table summarizes SH2D4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SH2D4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH2D4B shows lower tumor expression in LUAD, THCA, LUSC and KICH and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher SH2D4B RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p < 0.001).
This table shows molecular features associated with SH2D4B in patient tissues and cancer cell lines. In patient samples, SH2D4B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SH2D4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
